Hepatitis Forums

Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on April 26, 2017, 10:05:31 am

Title: Gilead’s Hep B Treatment Vemlidy Is Safer for Bones and Kidneys Than Viread
Post by: Hep Editors on April 26, 2017, 10:05:31 am

Gilead Sciences’ Vemlidy (tenofovir alafenamide, or TAF) is less toxic to bones and kidneys than the company’s Viread (tenofovir disoproxil fumarate, or TDF) when used as treatment for hepatitis B virus (HBV). Ninety-six-week data of two large trials also recently showed that switching from Viread to Vemlidy leads to improvement in a key liver enzyme level.

Researchers evaluated 96-week data from two randomized double-blind Phase III studies, called Studies 108 and 110, that compared Vemlidy to Viread among those who had or had not been treated for HBV before and who had HBeAg-negative or HbeAg-positive hep B.

Read more...
https://www.hepmag.com/article/gileads-hepatitis-b-treatment-vemlidy-safer-bones-kidneys-viread